Two strengths of ranitidine among 22 price concessions for November
The Department of Health and Social Care (DH) and the National Assembly for Wales have agreed concessionary prices for the following 22 items for November 2019 prescriptions.
An initial nine price concessions for the month were announced on November 19.
Certain batches of ranitidine-containing medicines have been subject to recall and quarantine, as the Medicines and Healthcare products Regulatory Agency (MHRA) investigates their potential contamination with N-nitrosodimethylamine (NDMA), which is a known risk factor for some cancers.
Last week (November 19), the MHRA announced the latest ranitidine-containing products to be recalled: Creo Pharma Limited's ranitidine oral solution 30mg/ml and Tillomed Laboratories Limited's ranitidine 150mg tablets.
Do these prices reflect the ones you have paid in November so far?